BRIACELL THERAPEUTICS CORP (BCTX) Fundamental Analysis & Valuation

NASDAQ:BCTX • CA1079303071

Current stock price

4.43 USD
+0.11 (+2.55%)
At close:
4.5198 USD
+0.09 (+2.03%)
After Hours:

This BCTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. BCTX Profitability Analysis

1.1 Basic Checks

  • In the past year BCTX has reported negative net income.
  • In the past year BCTX has reported a negative cash flow from operations.
  • In the past 5 years BCTX always reported negative net income.
  • BCTX had a negative operating cash flow in each of the past 5 years.
BCTX Yearly Net Income VS EBIT VS OCF VS FCFBCTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • BCTX has a Return On Assets of -88.22%. This is in the lower half of the industry: BCTX underperforms 72.67% of its industry peers.
  • BCTX has a Return On Equity of -95.86%. This is comparable to the rest of the industry: BCTX outperforms 44.96% of its industry peers.
Industry RankSector Rank
ROA -88.22%
ROE -95.86%
ROIC N/A
ROA(3y)-91.98%
ROA(5y)-72.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCTX Yearly ROA, ROE, ROICBCTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K 1.5K

1.3 Margins

  • BCTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCTX Yearly Profit, Operating, Gross MarginsBCTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BCTX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, BCTX has more shares outstanding
  • The number of shares outstanding for BCTX has been increased compared to 5 years ago.
  • BCTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCTX Yearly Shares OutstandingBCTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M
BCTX Yearly Total Debt VS Total AssetsBCTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • BCTX has an Altman-Z score of 1.45. This is a bad value and indicates that BCTX is not financially healthy and even has some risk of bankruptcy.
  • With a decent Altman-Z score value of 1.45, BCTX is doing good in the industry, outperforming 62.21% of the companies in the same industry.
  • BCTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.45
ROIC/WACCN/A
WACCN/A
BCTX Yearly LT Debt VS Equity VS FCFBCTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M

2.3 Liquidity

  • BCTX has a Current Ratio of 10.10. This indicates that BCTX is financially healthy and has no problem in meeting its short term obligations.
  • BCTX's Current ratio of 10.10 is fine compared to the rest of the industry. BCTX outperforms 79.65% of its industry peers.
  • A Quick Ratio of 10.10 indicates that BCTX has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 10.10, BCTX is doing good in the industry, outperforming 79.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.1
Quick Ratio 10.1
BCTX Yearly Current Assets VS Current LiabilitesBCTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BCTX Growth Analysis

3.1 Past

  • The earnings per share for BCTX have decreased strongly by -184.87% in the last year.
EPS 1Y (TTM)-184.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, BCTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.83% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y90.98%
EPS Next 2Y40.47%
EPS Next 3Y25.73%
EPS Next 5Y18.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCTX Yearly Revenue VS EstimatesBCTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2M 4M 6M 8M 10M
BCTX Yearly EPS VS EstimatesBCTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

1

4. BCTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BCTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCTX Price Earnings VS Forward Price EarningsBCTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCTX Per share dataBCTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80 -100

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BCTX's earnings are expected to grow with 25.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.47%
EPS Next 3Y25.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BCTX Dividend Analysis

5.1 Amount

  • BCTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BCTX Fundamentals: All Metrics, Ratios and Statistics

BRIACELL THERAPEUTICS CORP

NASDAQ:BCTX (4/17/2026, 8:00:02 PM)

After market: 4.5198 +0.09 (+2.03%)

4.43

+0.11 (+2.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10
Earnings (Next)06-15
Inst Owners1.05%
Inst Owner Change0%
Ins Owners0.05%
Ins Owner Change0%
Market Cap32.12M
Revenue(TTM)N/A
Net Income(TTM)-29.64M
Analysts80
Price TargetN/A
Short Float %3.91%
Short Ratio1.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.04
P/tB 1.04
EV/EBITDA N/A
EPS(TTM)-128.19
EYN/A
EPS(NY)-3.43
Fwd EYN/A
FCF(TTM)-4.27
FCFYN/A
OCF(TTM)-4.27
OCFYN/A
SpS0
BVpS4.26
TBVpS4.24
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -88.22%
ROE -95.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-91.98%
ROA(5y)-72.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.1
Quick Ratio 10.1
Altman-Z 1.45
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-184.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.93%
EPS Next Y90.98%
EPS Next 2Y40.47%
EPS Next 3Y25.73%
EPS Next 5Y18.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.91%
OCF growth 3YN/A
OCF growth 5YN/A

BRIACELL THERAPEUTICS CORP / BCTX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BRIACELL THERAPEUTICS CORP (BCTX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BCTX.


What is the valuation status of BRIACELL THERAPEUTICS CORP (BCTX) stock?

ChartMill assigns a valuation rating of 1 / 10 to BRIACELL THERAPEUTICS CORP (BCTX). This can be considered as Overvalued.


How profitable is BRIACELL THERAPEUTICS CORP (BCTX) stock?

BRIACELL THERAPEUTICS CORP (BCTX) has a profitability rating of 0 / 10.


What is the expected EPS growth for BRIACELL THERAPEUTICS CORP (BCTX) stock?

The Earnings per Share (EPS) of BRIACELL THERAPEUTICS CORP (BCTX) is expected to grow by 90.98% in the next year.